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In this issue of Cancer Cell, Cole and colleagues report a non-mutant mitochondrial protein (ClpP) that is
overexpressed in a wide range of acute myeloid leukemia (AML) cases, but not in normal hematopoietic pre-
cursors. This finding suggests a potentially unique therapeutic targeting opportunity for this difficult-to-treat
disease.In the era of deep sequencing and molec-
ular discovery, new cancer targets are
identified, investigated, and drugged
with increasing rapidity. As a result, the
landscape for many malignancies is
changing. Acute myeloid leukemia (AML)
has had numerous promising therapeutic
leads, but its close proximation to normal
hematopoiesis and genetic heterogeneity
have made impactful treatment success
elusive. Indeed, no therapy for this dis-
ease has been fully approved by regula-
tory agencies for more than 20 years.
Might this be due to a lack of sophisticat-
ion in applying precision medicine strate-
gies to the diverse genomic background
of AML or could it be the best ‘‘druggable
target’’ has not been identified? The lack
of progress in AML has prompted pursuit
of both hypotheses among AML investi-
gators. In this issue of Cancer Cell, Cole
et al. (2015) provide new hope that a
more universal target indeed exists in
this disease.
Mitochondria have been of interest in
cancer therapy since the 1950s, when
Warburg reported that cancer cells were
unique from surrounding tissues with
respect to their mechanisms for gener-
ating ATP and supporting cell growth.
He proposed that defects in mitochon-
drial mechanisms were not only respon-
sible for observed increased glycolysis,
but also for the transformation of a normal
cell to a cancerous one (Warburg 1956).
Although the Warburg effect holds true
in many instances, it fails to reconcile
inherent differences in energymetabolism
between proliferating disease cells and
the quiescent cancer stem cell popula-
tion, a fraction that resists chemotherapy
and perpetuates disease. In AML, thesecells lack a consistent immunopheno-
type, making identification and targeting
more difficult. Nevertheless, the eradica-
tion of this compartment remains a prom-
inent issue that all developing therapies
must address.
Recently Lagadinou et al. (2013) took a
novel, biologic approach to targeting leu-
kemia stem cells (LSCs) involving the
mitochondria. Instead of relying on tradi-
tional mechanisms, cell surface markers,
or mutations, they evaluated all AML cells
by energy metabolism. In this structure,
they more rigorously defined the LSC
population through colony-forming as-
says and xenograft studies and found
them to be more highly dependent on
mitochondrial ATP and unable to upregu-
late glycolysis to meet energy demands
even when challenged. This phenotype
sensitized the cells to anti-Bcl-2 mole-
cule ABT-263, which impaired oxidative
phosphorylation and led to cell death,
providing more evidence of the potential
efficacy of mitochondrial targeting thera-
pies (Lagadinou et al., 2013).
Previously, Skrtic et al. (2011) used a
genome-wide chemical screen to look
for anti-leukemic activity and came up
with tigecycline, an antibiotic that blocks
bacterial ribosomes. This compound’s
anti-leukemic activity is due to inhibition
of mitochondrial translation (Skrtic et al.,
2011). Based on this observation, Cole
et al. (2015) looked to identify which mito-
chondrial proteins were critical to prolifer-
ation using a small hairpin RNA (shRNA)
screen with an AML cell line and found ca-
seinolytic protease (ClpP) to be necessary
for cell survival, whereas other mitochon-
drial proteases were not. ClpP is a serine
protease that was first identified in bacte-Cancer Ceria, where it garnered interest as a poten-
tial target for anti-microbial therapy (Zeiler
et al., 2012). In mammals, ClpP is en-
coded by a nuclear gene, and the trans-
lated protein is transported into the
mitochondria and localized to the inner
membrane where it degrades mito-
chondrial proteins damaged by oxidative
stress (Figure 1A) (Corydon et al., 1998).
Cole et al. (2015) beganwith the discov-
ery that ClpP was overexpressed in 45%
of 511 primary AML samples, irrespective
of cytogenetics or mutational status,
compared to CD34+ cells from 21 healthy
controls. The authors hypothesized that
CLPP overexpression may be the result
of increased mitochondrial stress, an
end-result of several possible pathways
that obviates any correlation with a known
genomic subtype of the disease. Knock-
down of ClpP using shRNA decreased
the viability of cell lines that overex-
pressed this protein, but not that of
a cell line with baseline expression.
Furthermore, the authors demonstrated
a reduced engraftment into NOD-SCID
mice after knockdown of ClpP, suggest-
ing an effect on the LSC compartment
as well (Cole et al., 2015).
To evaluate potential systemic toxicity,
Cole et al. (2015) created a constitutive
Clpp knock-out mouse line that recapitu-
lated what has been described in other
Clpp knockout mouse models: smaller
size, congenital deafness, and infertility.
They further looked at the composition
of the bone marrow and found the
Clpp/ strain to have comparable
makeup to wild typemice aswell as a pre-
served ability for stem cells to repopulate
a marrow in transplant studies. These ex-
periments suggest no deleterious effectll 27, June 8, 2015 ª2015 Elsevier Inc. 747
Figure 1. ClpP’s Proposed Role in Oxidative Phosphorylation
(A) ClpP is a nuclear encoded serine protease that is translated in the cytoplasm and then trafficked into the mitochondria, where it is assembled into
tetradecamers with its chaperone protein ClpX.
(B) Based on protein interaction assays, ClpP associates with members of the electron transport chain, specifically succinate dehydrogenase subunit A (SDHA),
and other enzymes inherent to metabolism. Cole et al. (2015) hypothesized that ClpP plays an analogous role to cytosolic proteasomes and degrades dysfunc-
tional proteins within the mitochondria.
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are consequences in other compartments
resulting from loss of ClpP, they are not le-
thal and could be abrogated by only inter-
mittent or partial inhibition of the target,
giving a potential therapeutic window be-
tween normal tissue and AML cells. The
similarities between AML cells and normal
hematopoietic tissue have long frustrated
researchers looking for a unique target to
exploit. One promising target that con-
tinues to be explored is the IL-3 receptor
(CD123). Gill et al. (2014) generated a
very robust immunotherapeutic agent,
an anti-CD123 CAR T cell, and demon-
strated exciting results in in vitro and
in vivo models of AML. Unfortunately,
treatment with this agent also wiped out
the normal hematopoietic stem cell
compartment, dampening the enthu-
siasm for its clinical relevance (Gill et al.,
2014).
Having identified ClpP as a promising
target due to its overexpression in a high
proportion of AML cases and negligible
role in normal hematopoiesis, Cole et al.
(2015) looked to identify the specific pro-
tein interactions to help elucidate a mech-
anism of action. Aside from its chaperone
ClpX, they ascertained that ClpP interacts
most frequently with members of the
mitochondrial respiratory chain, specif-
ically succinate dehydrogenase subunit
A, a key component of complex II of the748 Cancer Cell 27, June 8, 2015 ª2015 Elserespiratory transport chain (Figure 1B).
Indeed, they subsequently demonstrated
quite elegantly that energy metabolism
dependence upon ClpP overexpression
exists in AML cells.
Cole et al. (2015) then tested A2-32-01,
a known ClpP inhibitor, and found that it
appeared to be specific to ClpP and did
not inhibit the cytosolic proteasome.
A2-32-01 was able to induce cell death
in the ClpP overexpressing cell lines, but
not in a cell line with low expression or a
control cell line lacking the ability to un-
dergo oxidative phosphorylation. Sepa-
rately, they showed that A2-32-01 did
not cause further decrease in viability or
growth of cells with a ClpP knockdown.
They examined the efficacy and toxicity
of A2-32-01 in vivo using a xenograft
mouse model, first using the OCI-AML2
cell line in SCID mice. They demonstrated
delayed tumor growth as well as
decreased ClpP enzymatic activity in
tumor tissue, suggesting an on-target ef-
fect and also absence of organ toxicity.
Finally, they looked at engraftment of pri-
mary AML samples into NOD-SCID mice
that were subsequently treated with A2-
32-01 and showed delayed engraftment
in the treated group. A2-32-01 serves as
a tool molecule for demonstrating the
potential effectiveness of targeting ClpP,
but it will need further optimization for
full clinical use.vier Inc.The laboratory work with ClpP by Cole
et al. (2015) provides a promising target
for AML investigation focused on the
mitochondria. Still, the data presented
suggest that this particular target may
span the gap between precision and
broad applicability and may represent an
opportunity for combination with other
mitochondrial-directed therapies. Indeed,
the influence of bcl-2-targeted inhibition
on oxidative phosphorylation in AML
combined with inhibiting ClpP could
represent an innovative combination for
AML. Some of the questions that remain
include: what other roles might ClpP
play, can a therapeutic window be ob-
tained in patients with AML, and will the
modifications needed to create a better
drug alter the binding profile and thera-
peutic efficacy? As drugs against prom-
ising targets such as ClpP move forward,
they should therefore be approached in a
rational manner as recently proposed by
Estey et al. (2015) to provide the best op-
portunity for success. Application early in
the natural history of the disease and in
combination strategies offers the greatest
opportunity to impact outcome for pa-
tients with this disease.REFERENCES
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Spranger and colleagues reported recently in Nature an inverse relationship between melanoma intrinsic
b-catenin signaling and intratumoral T cell infiltration, providing an explanation for potential mechanisms
of T cell exclusion. Further insights are needed into the mechanisms leading to a lack of T cell infiltration
of cancers and primary immune resistance.After decades of efforts, the war on cancer
has reached an exciting new turning point
with the promise of long-term remissions
in patients with different cancer histologies
treatedwith immune checkpoint inhibitors.
It reflects a fundamental change by fully
utilizing the power of the human immune
system to control and eradicate cancer.
Sustained responses have been reported
beyond the traditionally ‘‘immunotherapy
sensitive’’ tumor types such as melanoma
or renal cell carcinoma, evidenced by the
USFoodandDrugAdministrationapproval
of the anti-PD-1 antibody nivolumab to
treat the squamous subtype of non-small
cell lung cancer as a second-line therapy.
Full pipelines of immune modulatory
agents are in different stages of clinical
development for a wide variety of tumor
types. It is still unclear, however, why only
a percentage of patients within the same
tumor type respond to the therapy and
why certain tumors do not respond at all.
Studying the immune resistance mecha-
nisms in these patients and tumor types
would pave the way to the rational design
of combination strategies to improve
efficacy.The Wnt/b-catenin pathway is crucial in
embryonic development and adult tissue
homeostasis, including hematopoiesis,
cell migration, and wound repair (Kahn,
2014). Aberrant regulation of this pathway
has been linked to cancer development,
more aggressive behavior, and worse
prognosis in several types of cancers.
Mutations of b-catenin have been des-
cribed in melanoma cell lines (Rubinfeld
et al., 1997), and active WNT/b-catenin
signaling was reported in one third of
melanoma tumors. However, its signifi-
cance is a matter of debate, because
melanomas with a b-catenin signature
have been associated with lower prolifer-
ative index (Chien et al., 2009), more
favorable prognosis, and less aggressive
disease (Bachmann et al., 2005), adding
to the complexity of this topic.
In a recent publication in Nature,
Spranger et al., (2015) demonstrated
that tumor-intrinsic b-catenin signaling
might result in the lack of T cell
infiltration in melanoma models and in
patient-derived biopsies. As a first step,
the authors analyzed microarray gene
expression data from 266 human cuta-neous melanoma samples acquired from
the public domain and categorized these
samples into ‘‘T cell inflamed’’ and ‘‘non-
T cell-inflamed’’ subtypes based on rele-
vant gene expression. Pathway analysis
suggested the association of active b-cat-
enin signaling with the non-T cell-inflamed
cohort, which was a novel observation.
The authors then used previously es-
tablished genetically engineered mouse
models driven by conditional BRAFV600E
activation and PTEN deletion (BRAFV600E/
PTEN/), compared with an additional
stabilized b-catenin (BRAFV600E/PTEN//
Bcat-STA) melanoma mouse model
(Damsky et al., 2011). Melanomas in
these mice can be induced by local appli-
cation of tamoxifen, and the BRAFV600E/
PTEN//Bcat-STA phenotype was previ-
ously reported to be more aggressive with
high metastatic potential (Damsky et al.,
2011). Melanomas arising from mice with
active b-catenin were associated with
almost complete absence of T cells, and
the few remaining intratumoral T cells
showed predominantly a naive phenotype
with low PD-1, PD-L1, and LAG3 ex-
pression. When a neo-antigen (SIY) wasll 27, June 8, 2015 ª2015 Elsevier Inc. 749
